Sarepta Therapeutics’ (SRPT) “Sell” Rating Reiterated at HC Wainwright

HC Wainwright reissued their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Thursday,Benzinga reports. The firm currently has a $75.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on SRPT. UBS Group lifted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Needham & Company LLC dropped their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday, November 27th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Stock Up 1.0 %

SRPT stock traded up $1.21 during mid-day trading on Thursday, hitting $120.68. 114,520 shares of the company were exchanged, compared to its average volume of 1,212,671. Sarepta Therapeutics has a 1-year low of $89.92 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm’s 50 day simple moving average is $123.41 and its 200 day simple moving average is $131.36. The firm has a market cap of $11.53 billion, a P/E ratio of 96.54 and a beta of 0.77.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the company. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $31,000. Nkcfo LLC bought a new position in Sarepta Therapeutics in the 2nd quarter valued at $43,000. Sunbelt Securities Inc. grew its position in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the period. Huntington National Bank grew its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the period. Finally, Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.